Hydroxyethyl starch: Controversies revisited

Rashmi Datta, Rajeev Nair, Anil Pandey, Nitish Kumar, Tapan Sahoo
Department of Anaesthesiology & Critical Care, Army Hospital (R & R), Delhi Cantonment, India

Abstract

Hydroxyethyl starch (HES) family has been one of the cornerstones in fluid management for over four decades. Recent evidence from clinical studies and meta-analyses has raised few concerns about the safety of these fluids, especially in certain subpopulations of patients. High-quality clinical trials and meta-analyses have emphasized nephrotoxic effects, increased risk of bleeding, and a trend toward higher mortality in these patients after the use of HES solutions. Scientific evidence was derived from international guidelines, aggregated research literature, and opinion-based evidence was obtained from surveys and other activities (e.g., internet postings). On critical analysis of the current data available, it can be summarized that further large scale trials are still indicated before HES can be discarded.

Key words: Controversies, hydroxyethyl starch, colloids

Introduction

Hydroxyethyl starch (HES) comprises of a family of semi-synthetic, polydisperse colloid solutions made up of large ethylated, polymerized amylopectin molecules [Figure 1]. The HES-family differ widely in their physicochemical and pharmacokinetic properties, composition, and adverse effect profiles [Table 1, Figure 2].[1-3] HES solutions with average molecular weight (MW) of 70-130 kDa are classified as low MW (LMW HES), those with 200 kDa as medium MW (MMW HES) and those with a molecular weight >450 kDa as high MW (HMW HES) [Table 2].

The first-generation HES was introduced in the early 1970s as a replacement for human albumin [Figure 3]. The prolonged intravascular persistence along with restoration of cell-mediated and macrophage functions theorized that the solutions would have efficient hemodynamic stabilization in shock.[4,5]

Subsequent studies reported mixed evidence of benefits and significant adverse effects. Introduction of rapidly degradable HES solutions added new controversies. Fueling the controversies was the retraction (due to grounds of ethical and scientific misconduct) of studies reporting benefits of HES.[6] Recently, the European Medicines Agency (EMA) has recommended that HES be suspended in the European Union (EU).[7] The United States Food and Drug Administration (US FDA) also issued a warning on increased mortality, severe renal injury, and risk of bleeding, for use of HES solutions in some settings.[8]

Scientific evidence was derived from international guidelines, aggregated research literature, and opinion-based evidence was obtained from surveys and other activities (e.g., internet postings). In view of these controversies there is a need to revisit the use of HES.

Controversies

HES was introduced in the market without large phase III trials to evaluate the efficacy and safety. Reports of deterioration in renal functions in patients who had undergone renal transplantation as well as in critically ill patients soon started emerging.[9-13]

Some studies did not detect adverse effects even with large doses of starch solutions except for impaired coagulation; however, these were limited by their design, small size, and short observation periods.[14-16] The ability of HES to interfere with coagulation had already prompted warning labels and...
dose limitations.[17,18] Further, long-term tissue storage of the colloid was labeled potentially toxic, considered responsible for the observed increase in mortality at 90 days, particularly with higher and cumulative doses.[19-21]

A multicentric study, the Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) compared Ringer’s lactate with 10% HES 200/0.5 for volume replacement therapy in 537 patients with severe sepsis. The authors concluded that colloids, led to an increased incidence of renal failure with a non-significant but definite, trend toward higher 90-day mortality.[22]

The Scandinavian Starch for Severe Sepsis/Septic Shock (6S) trial compared Ringer’s acetate to 6% HES 130/0.42 for fluid resuscitation in 800 septic patients. The authors also reported an increased incidence of renal replacement therapy (RRT) after HES and a significantly higher 90-day mortality.[23]

The HES or Saline for Fluid Resuscitation in Intensive Care (CHEST) trial randomized 7000 patients, at mean 11 h after intensive care unit (ICU) admission, to receive saline or 6% HES 130/0.4 for fluid resuscitation. The authors found no differences in mortality or renal function according to the RIFLE criteria, but an increased incidence of RRT after HES infusion in the non-adjusted analyses.[24]

The Surviving Sepsis Campaign, 2012 Guidelines, which is a collaboration between the US Society of Critical Care

| Table 1: Physiochemical properties of the HES family |
|-----------------------------------------------|
| **Property** | **Available Choices** | **Clinical Effects** |
|----------------|------------------------|----------------------|
| Concentration  | 6% or 10%              | Determines the initial volume effect 6% is iso-oncotic with a volume effect of 100% 10% is hyper-oncotic with a volume effect 145% |
| Average molecular weight | Low (~70 kDa), medium (200 kDa) or high (~450 kDa) | Determines the intravascular persistence, the duration and extent of tissue storage, side effects such as itching, anaphylaxis, effect on blood coagulation, especially on factor VIII and von Willebrand factor and renal functions |
| Molar substitution | Low (0.45-0.58) or high (0.62-0.70) | Determines the water solubility and molecular weight Determines the rates of HES degradation by serum α-amylase High C2/C6 ratios of >8 are more slowly degraded |
| C2/C6 ratio | | Balanced HES preparation has overall less negative effects on hemostasis and platelet aggregation than the saline preparation |
| Solvents used | Normal saline and ringer solution | Potato-derived HES exhibits a faster clearance from the circulation as it has a lower average degree of branching and a higher degree of esterification with phosphoric acid |
| Source of starch | Potato-derived and waxy maize-derived | |

**HES** = Hydroxyethyl starch

| Table 2: Classification of HES by molar substitution |
|-----------------------------------------------|
| **Molar substitution** | **Classification** | **Description** | **Trade names** |
|----------------|-------------------|----------------|----------------|
| 0.7 | Hetastarch | High molecular weight HES | Hespan, Plasmasteril, Hexend (Balanced) |
| 0.6 | Hexastarch | High-medium molecular weight HES | Elohes |
| 0.5 | Pentasrarch | Medium molecular weight HES | HAES-Steril, Pentaspan, Hemohes |
| 0.4 | Tetrastarch | Low molecular weight HES | Voluven, Venofundin, Tetraspan (Balanced), Volulyte (Balanced), Plasma Volume Readybag (Balanced) |

**HES** = Hydroxyethyl starch
The three trials, VISEP, 6S and the CHEST trail evaluated HES along with Ringer’s lactate, Ringer’s acetate and saline respectively.\textsuperscript{[22-24]} On analysis, the initial 6-h phase was not evaluated in any of the trials. In all three, colloids were given initially and patients subsequently randomized to two groups. Hemodynamic stabilization was defined by the usual recommended “goals” (Goal Directed Fluid Therapy and Surviving Sepsis Guidelines). Majority of patients in the VISEP trail had median values of mean arterial pressure (MAP), central venous pressure (CVP), central-venous oxygen saturation (ScvO\textsubscript{2}) and lactate at the time of randomization as 75 mmHg, 12 mmHg, 74\% and 2.2 mmol/l, respectively. In the 6S trail, the baseline median values of CVP, ScvO\textsubscript{2} and lactate were 10 mmHg, 75\% and 2.0 mmol/l, respectively. Baseline values in the HES group in the CHEST trail were MAP 74 mmHg, CVP 9.5 mmHg and lactate 2.1 mmol/l. As per general recommendations, colloids are not indicated once these goals have been achieved.\textsuperscript{[28-31]}

In the VISEP trial, 58\% of the “crystalloid” group had already received 1 L of HES for initial resuscitation and a further 33\% in this group received colloids during the trial. In the “colloid” group, a hyperoncotic solution was given to patients in daily and cumulative dosages beyond any manufacturer’s recommendation. In the 6S trail, 60\% of the “crystalloid” group had already received up to 1 L of colloid for initial resuscitation and a further 32\% received colloids during the trial. A total of 216 (27\%) patients in both groups were included in the 90-day follow-up under the intention-to-treat principle but had discontinued the trial fluid. 508 patients in the saline group in the CHEST trail had received HES prior to randomization. Use of other colloids was not reported. Moreover, the protocol was violated 953-times in 634 (9.5\%) patients by infusing the wrong study fluid. All these patients remained in the trial.\textsuperscript{[28,30]}

In the 6S trail, in the 90-day period, 87 patients (22\%) assigned to HES 130/0.42 were treated with RRT versus 65 patients (16\%) assigned to Ringer’s acetate (relative risk, 1.35; 95\% confidence interval [CI], 1.01-1.80; \(P = 0.04\)), similar to a previously published report.\textsuperscript{[32]} In both, the mortality started to increase around 20 days with HES, which might be due to the late adverse effects of HES. A high fraction of HES is taken up and deposited in the tissues, where it cannot be metabolized and acts as a foreign body.\textsuperscript{[1,2,33,34]}

In the CHEST trial, no differences in mortality or renal function, but an increased incidence of RRT after HES infusion in the non-adjusted analyses were found. The authors tried to explain this by \textit{post-hoc} tests, showing higher relative risks for the HES receivers to develop renal insufficiency states i.e., “RIFLE-R” (risk of renal failure) or “RIFLE-I” (kidney injury). In the adjusted analysis (a standard procedure
to eliminate age, gender or severity of illness difference), no difference in the incidence of RRT was detected. Furthermore, 54.0% (1788/3309) of the HES group were at risk as per the RIFLE-R criteria as compared to 57.3% (1912/3335) in the saline group and as per the “RIFLE-I” criteria, 34.6% (1130/3265) of the HES group were at risk as compared to 38% (1253/3300) in the saline group [Table 1]. Fewer patients in the HES group as compared to the saline group had urine output <0.5 ml/kg/h for 6 h (52.7% vs. 56.5%) and <0.5 ml/kg/h for 12 h (36.2% vs. 39.7). Moreover, 36% of the patients had acute renal failure (ARF) at the time of randomization and should not have been included in the study.\textsuperscript{[24,30,31]}

HMW, a poorly biodegradable HES preparation, presents an independent risk-factor for AKI in patients with sepsis or septic shock.\textsuperscript{[13]} This was ignored in the VISEP trial. Furthermore, the exclusion criterion of a serum-creatinine value of >320 micromol/l (>3.6 mg/dl) was double that of the manufacturer’s specification.

In addition, in the 6S trial, hemodynamic parameters have been reported only for the first 24 h. The data on mechanical ventilation, length of hospital and ICU stay and the individual cause of death has not been reported. In the CHEST trial, 30% of the patients were septic and in this subgroup no differences in mortality, renal failure or RRT were observed.\textsuperscript{[29,30]}

The VISEP, 6S and CHEST study are limited to the management of the critically ill patient and as mentioned are silent on the management strategies prior to ICU admission or have violated prescribed daily limits for the administration of HES and or received other forms of fluid/colloid therapy. In addition, extrapolation of these findings to patients receiving or requiring HES for resuscitation, with various causes for hypovolemia including those with trauma and in the peri-operative period, would be an extreme response to studies specifically designed to look at a subset of the patient population.

## Controversies Revisited

Tissue storage of HES molecules is the proposed mechanism underlying complications such as anaphylaxis, pruritus, increased rates of ARF and need for RRT. Direct coating by the HES molecules is implicated in coagulopathy and bleeding. An increase in amylase levels is the result of induced metabolism.\textsuperscript{[1,2,34]}

HES can persist indefinitely intracellular as there are no known intracellular catabolic enzymes. At the present time, the precise mechanism of complete elimination of HES is still the subject of discussion.\textsuperscript{[2,5,34,35]} Cumulative doses cause HES to accumulate in the body. Two studies\textsuperscript{[36,37]} used \textsuperscript{14}C radioactive-labeled 130/0.4, 200/0.5 and 450/0.7 HES in a multi-dosing regimen of 0.7 g/kg body weight/day for 18 days in rats. The authors concluded that even at day 52, the remaining activity in the kidneys was low, but indicated that continued excretion of residual HES was still occurring even in the case of lower whole-body storage for HES 130/0.4.

HES molecules with a high degree of substitution (with a molar substitution >0.4) and a high C2/C6 ratio\textsuperscript{[1,2,5,34,35,38]} are taken up by the monocyte-macrophage system of various tissues through pinocytosis. Accumulation is dose and time-dependent. Tissues include blood, liver, striated muscle, spleen, intestine and skin. In the kidneys, the lesion is described as “osmotic nephrosis” of the proximal tubular epithelial cells.\textsuperscript{[1,38-42]}

### Clinical Implications of Tissue Accumulation

#### Pruritus

The incidence of HES-induced pruritus has been variously reported as none to 55% of patients.\textsuperscript{[2,5,34,35,43,44]} Ellger et al. in their study found no incidence of pruritis in any of the 40 patients undergoing elective urologic surgery; although relatively high doses derived HES 130/0.4 (6%) were given.\textsuperscript{[44]} Long-term follow-up of 295 patients of the 6S trial resuscitated with HES was done to assess the health-related quality of life (HRQoL) and the occurrence of pruritus. The patients assigned to resuscitation with HES 130/0.4 had worse self-perceived HRQoL than those assigned to Ringer’s acetate, whereas there were no statistically significant differences in the occurrence of pruritus (49% vs. 43%). The group differences were mainly in the scales of vitality and mental health. There was no difference in the physical component summary scores between groups.\textsuperscript{[45]}

#### Non-immunologic anaphylaxis

This has been well documented, and may include angioedema, hypotension, and urticaria. True anaphylaxis, due to specific antibody production (IgE), is believed to be extremely rare.\textsuperscript{[1,34,35,46,47]}

No data on the incidence of anaphylactic reactions after intravenous administration of the HES 130/0.4 are available. The 1-year post-approval Adverse Event Review of US FDA in 2009 reported only one case with a past medical history of spina bifida and multiple orthopedic surgeries who received HES 130/0.4 during orthopedic surgery in 2007. 2 h after induction
of anesthesia, the patient suffered an anaphylactic reaction and severe hypotension. The patient had also received treatment with antibiotics (ceftriaxone, Cloran, and Cefuroxime) which were suspected as a possible cause of the allergic reaction. The patient was later re-exposed to three different cephalosporins but did not experience any allergic symptoms. The patient was then re-challenged with increasing doses of HES 130/0.4 (3 mL, 10 mL and 30 mL); after the 30 mL dose, the patient developed urticaria, redness, pruritus and bronchial symptoms. These symptoms were treated with steroids and anti-histamines and resolved after an hour. The patient had a history of concomitant allergies to pollen and latex.\[48\]

It is unlikely that the modifications of the MW, molecular substitution and the C2/C6 ratio could have resulted in increased anaphylactic potency, because histamine liberation appears to be induced by the substance itself (starch) and not by the modifications of the substrate.\[1,2,4,5,34\]

**Acute renal injury**

Legendre et al. have reported 80% rate of “osmotic nephrosis lesions” in transplanted kidneys after administration of MMW HES (200/0.62) to brain-dead donors. These, however, had no adverse effects on graft function or serum creatinine after transplantation.\[62\] Two studies with 63 and 62 patients each concluded that choice of colloid had no impact on renal parameters and outcome in patients with pre-existing renal dysfunction undergoing elective abdominal aortic surgery.\[49,50\] Neff, et al. demonstrated that use of high doses of 6% HES 130/0.4 in neurosurgical patients (up to 66 L over 21 days) was not associated with deteriorating kidney function after 7 days.\[51\] Martin et al. found no evidence for renal dysfunction caused by modern waxy maize-derived HES 130/0.40 in surgical patients.\[52\]

Wiedermann concluded that HES possesses a significant negative impact on renal function. They, however, did not elaborate the types of HES preparations used, patients type or disease condition, pre-existing kidney dysfunction or fluid regimen used.\[53\] A recent Cochrane meta-analysis opined that all HES products increase the risk in AKI and RRT in all patient populations and a safe volume of any HES solution has yet to be determined.\[54\]

In severe sepsis, there are concerns of increased mortality though significantly less volume was required to achieve the hemodynamic goals in the initial phase of fluid resuscitation.\[54,56\] Zhong et al. concluded that the severity score is improved in HES, but the CI are wide.\[57\]

Newer formulations of HES and more focused indications for use show benefit on surrogate endpoints, but these trials are currently underpowered to ensure safety. Hence HES is currently not recommended for sepsis, those with previous mild to severe renal dysfunction, the elderly and those receiving high-dose therapy.\[54-58\]

**Coagulation disturbances**

HMW and MMW-HES preparations (200-450/0.5-0.7) had shown to induce a decrease in factor VIII activity, von Willebrand factor (vWF) antigen and factor VIII-related ristocetin cofactor due to dilution as well as coating of the platelets. As a result, there is reduced binding to platelet membrane receptor proteins GPIb and GPIIb/IIIa and decreased platelet adhesion. The effect of both MMW and LMW HES is less.\[2,58-61\]

Felfernig M showed that LMW HES with MS <0.5 effects the clot maturation process significantly less than other HES preparations.\[62\] I Gallandat Huet et al. compared HES 130/0.4 with HES 200/0.5 in coronary artery bypass grafting patients. In this study, vWF increased significantly more in the HES 130/0.4 treated patients. Blood loss and transfusion requirements were lower in patients receiving HES 130/0.4, indicating considerable benefits with HES 130/0.4.\[63\]

Mittermayr et al. have reported the effects of 20 mL/kg of lactated Ringer (LR), HES 200/0.5, and HES 130/0.4 on expression of platelet membrane glycoprotein cluster differentiation (CD) CD42b, CD41/61, and CD62p in vivo on non-stimulated platelets and adenosine diphosphate-activated platelets. Platelet dysfunction was observed in both HES groups, with faster recovery of platelets function after HES 130/0.4 than HES 200/0.5.\[64\]

However, when blood samples from healthy donors were diluted (30 and −60%) using crystalloids (saline, Ringer’s lactate, Plasmalyte [TM]) or colloids (6% HES130/0.4, 5% human albumin, and gelatin), HES 130/0.4 had the most deleterious effect on hemostasis parameters.\[65\] HES 130/0.4 has similar adverse effects as HES 200/0.5. Both types of HES impair coagulation capacity and stimulate pro-inflammatory platelet function.\[66\]

**Peri-operative period**

LMW HES has been shown to be safe in cardiovascular surgery\[67-70\] and liver transplant.\[71\] In major abdominal surgeries Staikou et al. demonstrated that HES 130/04-0.42 have a tendency toward reduced coagulability on the thrombelastography. HES 130/0.4 and HES 130/0.42 were equally safe when administered in doses up to 30 ml/kg.\[72\] In 100 patients undergoing elective surgery post trauma 100% patients in the gelatin group, 84.2% patients in the NS group, 94.4% patients in the RL group, and 66.7% patients in the
HES group were hypocooagulable (R time >14 min) in the post-operative period.[73] Hamaji et al. demonstrated that during hip arthroplasty, patients treated with hypervolemic hemodilution with HES 130/0.4 required less transfusion and lower infection rate compared to LR solution.[74]

Monitoring and minimizing pulse pressure variation by 6% HES 130/0.4 loading during gastrointestinal surgery has been shown to improve post-operative outcomes and decreases the discharge time of patients.[75]

Regarding prevention of maternal hypotension for cesarean sections, three strategies of colloid preload, colloid coload and crystalloid coload are equivalent for the prevention and a reduced need for vasopressors. Crystalloid preload is not as effective as any of those three strategies.[76] No difference was reported in the cardiac output, vasopressor requirements or hemodynamic stability on colloid or crystalloid coload.[77]

More studies are required utilizing the entire range of tests on platelet functions and coagulation profiles.[78-80]

**HES in traumatic and non-traumatic brain injury**

Serious complications of HES administration have been repeatedly demonstrated in clinical trials of acute ischemic stroke and other brain injuries, prompting premature termination of several randomized trials.[2,5,26,34]

Safety of HES solutions have been typically assessed in highly selected low-risk patient populations receiving relatively small HES doses, hence the results cannot be generalized to routine clinical practice.[51,81] In the present scenario, considering the cerebral and other systemic adverse effects coupled with existing higher mortality data, colloids do not seem to be fluid of choice for resuscitation in patients with TBI.[82]

**HES in burns resuscitation**

During Operation Iraqi Freedom, a protocol for the difficult fluid resuscitation was developed using albumin if projected 24-h resuscitation requirements exceed 6 ml/kg/% burn. The Israeli Haifa formula combines plasma and crystalloid and recommends substitution of colloids in part of the Fresh Frozen Plasma dosage.[26,83]

HES facilitated improved hemodynamics, oxygen delivery and prolonged plasma expansion yet concerns regarding the adverse effects of starches, particularly on coagulation, limited their use. However, LMW HES may exert beneficial effects on endothelial function by stabilization of fragile cell membranes or by avoiding endothelial swelling. Moreover, HES 130/0.4, because of the heavy hydroxyethylation at the C-2 position, may promote specific interactions with the endothelial glycocalyx and thereby inhibit leakiness.[26,34,35,61]

**Organ donors**

Blasco et al. used HES 130/0.4 or HES 200/0.62 for resuscitation of brain-dead donors. HES 130/0.4 was associated with a better effect on renal function 1 month and 1 year after transplantation. S. Creatinine was significantly lower in the HES 130/0.4 treated donors.[84]

Although, there are no studies comparing HES 130/0.4 and crystalloids in organ donors, it is recommended that any new colloid should be introduced into clinical practice only after its safety parameters are established.[85]

**Trauma and hemorrhagic shock**

There is still no consensus regarding the optimal treatment of hypovolemia in trauma patients. ATLS recommends the use of Ringer’s lactate solution in trauma whereas the USA Institute of Medicine recommends a Ringer’s lactate-based volume-replacement strategy.[26,86]

Crystalloids are often recommended as the first choice to treat hemorrhage due to low cost and easy availability. A randomized, controlled, double-blind study of 115 severely injured patients requiring >3 L of fluid resuscitation showed that the biochemical markers of resuscitation and renal function were better in those who received HES 130/0.4 as compared to saline after penetrating trauma. Outcomes were similar after blunt trauma, although numbers in these subgroups were modest.[87]

LMW HES is used and advocated by various militaries for pre-hospital, low-volume boluses hemorrhagic shock. HES 130/0.4-0.42 are associated with beneficial effects beyond their volume-replacement properties (e.g., improving micro-perfusion, capillary integrity, inflammatory response, and endothelial integrity).[88] Several near-fatal hemorrhage models have demonstrated that LMW HES is associated with significantly lower mortality compared with Ringer’s lactate.[89] In case both HES and a crystalloid is used, peripheral accumulation of the latter is promoted by HES.[90]

A multicenter, randomized clinical trial stratified by case mix (sepsis, trauma, or hypovolemic shock without sepsis or trauma), the Therapy in the Colloids Versus Crystalloids for the Resuscitation of the Critically Ill (CRISTAL) trial among ICU patients with hypovolemia opined that the use of colloids versus crystalloids did not result in a significant difference in 28-day mortality. Although 90-day mortality was lower among patients receiving colloids, this finding should be considered exploratory and requires further study before reaching conclusions about the efficacy.[91]
Conclusions

The HES family has evolved since its introduction almost four decades ago. Lower MW and MS have improved its safety profile. Newer formulations of HES and more focused indications for use show benefit on surrogate endpoints, but these trials are currently underpowered to ensure safety. Most studies about adverse effects have either been meta-analysis of small trials or have compared HES with another colloid. The effects of HES on coagulation parameters are well-documented and hence are a cause for concern.

The increased need for RRT in patients receiving HES was not a cause for concern when adjusted for confounding variables in some trials.

The use of HES cannot be condemned yet and though large RCT’s are needed, given the current importance given to the European pharmacovigilance ban and US FDA warning, it will take some time for such trials to happen. In addition, in the absence of HES for resuscitation, the role for Ringers acetate/lactate will be under the spotlight and given the large volumes needed, probably the acetated solutions will find favor.

References

1. Treib J, Baron JF, Grauer MT, Strauss RG. An international view of hydroxyethyl starches. Intensive Care Med 1999;25:258-68.
2. Westphal M, James ME, Koekz-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: Different products — Different effects. Anesthesiology 2009;111:187-202.
3. Ertmer C, Rehberg S, Van Aken H, Westphal M. Relevance of non-albumin colloids in intensive care medicine. Best Prac Res Clin Anaesthesiol 2009;23:193-212.
4. Mitra S, Khandelwal P. Are all colloids same? How to select the right colloid? Indian J Anaesth 2009;53:592-607.
5. Van Der Linden P, James M, Mythen M, Weiskopf RB. Safety of modern starches used during surgery. Anesth Analg 2013;116:35-48.
6. Editors-in-Chief statement regarding published clinical trials conducted without IRB approval by Joachim Boldt. Minerva Anestesiol 2011;77:562-3.
7. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/Reference/Human_reference_prac_000012.jsp&mid=WCOb01ac05805c16f.
8. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM325690.pdf.
9. Webb AR, Barclay SA, Bennett ED. In vitro colloid osmotic pressure of commonly used plasma expanders and substitutes: A study of the diffusibility of colloid molecules. Intensive Care Med 1989;15:116-20.
10. Schlumpf R, Morel P, Loveras JJ, Condie RM, Matas A, Kurje J, et al. Examination of the role of the colloids hydroxyethylstarch, dextran, human albumin, and plasma proteins in a modified UW solution. Transplant Proc 1991;23:2362-5.
11. Davidson LJ. Renal impact of fluid management with colloids: A comparative review. Eur J Anaesthesiol 2006;23:721-38.
12. Ragaller MJ, Theilen H, Koch T. Volume replacement in critically ill patients with acute renal failure. J Am Soc Nephrol 2001;12 Suppl 17:S33-9.
13. Schortgen F, Lacherade JC, Bruneel F, Cattaneo J, Hemery F, Lemaire F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 2001;357:911-6.
14. Wiesen P, Canivet JL, Ledoux D, Rodiger L, Damas P. Effect of hydroxyethylstarch on renal function in cardiac surgery: A large scale retrospective study. Acta Anaesthesiol Belg 2005;56:257-63.
15. Beyer R, Harmening U, Rittmeyer O, Zimmel S, Mieck F, Kazmaier S, et al. Use of modified fluid gelatin and hydroxyethyl starch for colloid volume replacement in major orthopaedic surgery. Br J Anaesth 1997;78:44-50.
16. Vogen N, Bothner U, Brinkmann A, de Petronici R, Georgieff M. Peri-operative tolerance to large-dose 6% HES 200/0.5 in major urological procedures compared with 5% human albumin. Anaesthesia 1999;54:121-7.
17. Haynes GR, Havdich JE, Payne KJ. Why the Food and Drug Administration changed the warning label for hetastarch. Anesthesiology 2004;101:560-1.
18. Jonville-Béra AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand’s disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001;345:622-3.
19. Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005;5:1120-9.
20. Christidis C, Mal F, Ramos J, Senejoux A, Callard P, Navarro R, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001;35:726-32.
21. Schmidt-Hieber M, Loddenkemper C, Schwartz S, Arntz G, Thiel E, Notter M. Hydrops lysosomalis generalisatus — An underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006;77:83-5.
22. Reinhart K, Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, et al. Study protocol of the VISEP study. Response of the SepNet study group. Anaesthesist 2008;57:723-8.
23. Perner A, Haase N, Guttermorensen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012;367:124-34.
24. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A,Gattas D, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012;367:1901-11.
25. Dellinger RP, Levy MM, Rhodes A, Alnane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
26. Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Sagmeister K, Kazmaier S, et al. Use of modified fluid gelatin and hydroxyethyl starch for colloid volume replacement in critically ill patients. Intensive Care Med 2012;38:368-83.
27. Health Canada: Important Safety Information on Drugs (RA-34299). [Posted on 2013 Jun 24].
28. Zander R, Boldt J, Engellmann L, Merzluft F, Sirtl C, Stuttman R. The design of the VISEP trial. Critical appraisal. Anaesthesist 2007;56:71-7.
29. Hartog CS, Brunkhorst FM, Engel C, Meier-Hellmann A, Ragaller M, Welte T, et al. Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use? Wien Klin Wochenschr 2011;123:145-55.
30. Chappell D, Jacob M. Hydroxyethyl starch: the importance of being honest. Scand J Trauma Resusc Emerg Med 2013;21:61.
31. Choi HS. Respiratory review of 2013: Critical care medicine. Tuberc Respir Dis (Seoul) 2013;75:1-8.
32. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.

33. Bellmann R, Feistritzer C, Wiedermann CJ. Effect of molecular weight and substitution on tissue uptake of hydroxethyl starch: A meta-analysis of clinical studies. Clin Pharmacokinet 2012;51:225-36.

34. Boldt J. Modern rapidly degradable hydroxyethyl starches: Current concepts. Anesth Analg 2009;108:1574-82.

35. Wittbrodt P, Haase N, Butowska D, Winding R, Poulsen JB, Perner A, et al. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney due to hydroxyethyl starch infusion. Eur Surg Res 1976;8:389-99.

36. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F, Repperling F. Tissue storage after multiple infusions in rats. Drugs R D 2003;4:331-8.

37. Bellmann R, Feistritzer C, Wiedermann CJ. Effect of molecular weight and substitution on tissue uptake of hydroxethyl starch: A meta-analysis of clinical studies. Clin Pharmacokinet 2012;51:225-36.

38. Ginz HF, Gottschall V, Schwarzkopf G, Walter K. Excessive tissue storage of colloids in the reticuloendothelial system. Br J Anaesth 1999;82:510-5.

39. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W. Tissue deposition of hydroxyethyl starch (HES): Dose-dependent and time-related. Anaesthesist 1998;47:330-4.

40. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 2002;95:544-51.

41. Leuschner J, Thervet E, Page B, Percheron A, Noël LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342:248-9.

42. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004;139:552-63.

43. Kozek-Langenecker SA. The effects of hydroxyethyl starch on renal function, thrombin generation and clot firmness: Effects of different fluid therapies: Effects on kidney function. Cochrane Database Syst Rev 2013;7:CD007594.

44. Sirtl C, Laubenthal H, Jurecka W. Hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003;96:1453-9.

45. Martin C, Jacob M, Vicaud E, Guidet B, Van Aken H, Kurz A. Effect of waxy maize-derived hydroxethyl starch 130/0.4 on renal function in Surgical patients. Anesthesiology 2013;118:387-94.

46. Martin C, Jacob M, Vicaud E, Guidet B, Van Aken H, Kurz A. Effect of waxy maize-derived hydroxethyl starch 130/0.4 on renal function in Surgical patients. Anesthesiology 2013;118:387-94.

47. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008;8:1.

48. Mutter TC, Ruth CA, Dart AB. Hydroxethyl starch (HES) versus other fluid therapies: Effects on kidney function. Cochrane Database Syst Rev 2013;7:CD007594.

49. Martin C, Jacob M, Vicaud E, Guidet B, Van Aken H, Kurz A. Effect of waxy maize-derived hydroxethyl starch 130/0.4 on renal function in Surgical patients. Anesthesiology 2013;118:387-94.

50. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. Modern rapidly degradable hydroxyethyl starches: Current concepts. Anesth Analg 2009;108:1574-82.

51. Neff TA, Doelberg M, Junghenrich C, Sauerland A, Spahn DR, Stocker R. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003;96:1453-9.

52. Martin C, Jacob M, Vicaud E, Guidet B, Van Aken H, Kurz A. Effect of waxy maize-derived hydroxethyl starch 130/0.4 on renal function in Surgical patients. Anesthesiology 2013;118:387-94.

53. Martin C, Jacob M, Vicaud E, Guidet B, Van Aken H, Kurz A. Effect of waxy maize-derived hydroxethyl starch 130/0.4 on renal function in Surgical patients. Anesthesiology 2013;118:387-94.

54. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008;8:1.

55. Mutter TC, Ruth CA, Dart AB. Hydroxethyl starch (HES) versus other fluid therapies: Effects on kidney function. Cochrane Database Syst Rev 2013;7:CD007594.

56. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008;8:1.

57. Hertog CS, Welte T, Schlattmann P, Reinhart K. Fluid replacement with hydroxyethyl starch in critical care — A reassessment. Dtsch Arztebl Int 2013;110:443-50.

58. Zhong JZ, Wei D, Pan HF, Chen YJ, Liang XA, Yang ZX, et al. Colloid solutions for fluid resuscitation in patients with sepsis: Systematic review of randomized controlled trials. J Emerg Med 2013;45:485-95.

59. Haase N, Perner A, Hanningsen LI, Siegmund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: Systematic review with meta-analysis and trial sequential analysis. BMJ 2013;346:f839.

60. Franz A, Bräunlich P, Gamsjäger T, Felfernig M, Gustorff B, Kozeck-Langenecker SA. The effects of hydroxyethyl starch varying of molecular weights on platelet function. Anesth Analg 2001;92:1402-7.

61. Fenger-Eriksen C, Tønnesen E, Ingerslev J, Sørensen B. Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. J Thromb Haemost 2009;7:1099-105.

62. Tataria T, Itani M, Sugi T, Fujita K. Physical plugging does not account for attenuation of capillary leakage by hydroxyethyl starch 130/0.4: A synthetic gel layer model. J Biomed Mater Res B Appl Biomater 2013;101:85-90.

63. Felfernig M, Franz A, Bräunlich P, Fohringer C, Kozeck-Langenecker SA. The effects of hydroxyethyl starch solutions on thromboelastography in preoperative male patients. Acta Anaesthesiol Scand 2003;47:70-3.

64. Gallandat Huert RC, Siemons AW, Baus D, van Roeyen-Butijn WT, Haagenaars JA, van Oeveren W, et al. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-15.

65. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: The role of fibrinogen administration. Anesth Analg 2007;105:905-17.

66. Caballo C, Escolar G, Diaz-Ricart M, Lopez-Vilchez I, Lozano M, Cid J, et al. Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: Effects of different coagulation factor concentrates. Blood Transfus 2013;11:391-9.
ethyl starch solution after coronary artery bypass surgery. Cardiovasc J Afr 2012;23:428-31.

69. Ertmer C, Wulf H, Van Aken H, Friederich R, Mahi C, Bepperling F, et al. Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients. Minerva Med 2012;103:111-22.

70. Kvalheim VL, Farstad M, Steien E, Mongstad A, Borje BA, Kvitting PM, et al. Infusion of hypertonic saline/starch during cardiopulmonary bypass reduces fluid overload and may impact cardiac function. Acta Anaesthesiol Scand 2010;54:485-93.

71. Mukhtar A, Aboulfetouh F, Obayah G, Salah M, Emam M, Khater Y, et al. The safety of modern hydroxyethyl starch in living donor liver transplantation: A comparison with human albumin. Anesth Analg 2009;109:924-30.

72. Staikou C, Paraskeva A, Fassoulaki A. The impact of 30 ml/kg hydroxyethyl starch 130/0.4 vs hydroxyethyl starch 130/0.42 on coagulation in patients undergoing abdominal surgery. Indian J Med Res 2012;136:445-50.

73. Sawhney C, Subramanian A, Kaur M, Anjum A, Albert V, Soni KD, et al. Assessment of hemostatic changes after crystalloid and colloid fluid preloading in trauma patients using standard coagulation parameters and thromboelastography. Saudi J Anaesth 2013;7:48-56.

74. Hamaji A, Hajjar L, Caiero M, Almeida J, Nakamura RE, Osawa EA, et al. Volume replacement therapy during hip arthroplasty using hydroxyethyl starch (130/0.4) compared to lactated Ringer decreases allogeneic blood transfusion and postoperative infection. Rev Bras Anestesiol 2013;63:27-35.

75. Zhang J, Qiao H, He Z, Wang Y, Che X, Liang W. Intraoperative fluid management in open gastrointestinal surgery: Goal-directed versus restrictive. Clinics (Sao Paulo) 2012;67:1149-55.

76. Loubert C. Fluid and vasopressor management for Cesarean delivery under spinal anesthesia: Continuing professional development. Can J Anaesth 2012;59:604-19.

77. McDonald S, Fernando R, Ashpole K, Columb M. Maternal cardiac output changes after crystalloid or colloid coload following spinal anesthesia for elective cesarean delivery: A randomized controlled trial. Anesth Analg 2011;113:803-10.

78. Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, Kukkonen SI, Niemi TT. Hydroxyethyl starches and dextran during hip replacement surgery: Effects on blood volume and coagulation. Anesth Analg 2009;108:30-6.

79. Bang SR, Kim YH, Kim GS. The effects of in vitro hemodilution with 6% hydroxyethyl starch (HES) (130/0.4) solution on thrombelastograph analysis in patients undergoing liver transplantation. Clin Transplant 2011;25:450-6.

80. Schick MA, Isbary JT, Stueber T, Brugger J, Stumpner J, Schlegel N, et al. Effects of crystalloids and colloids on liver and intestine microcirculation and function in cecal ligation and puncture induced septic rodents. BMC Gastroenterol 2012;12:179.